Structural characterization of MAM01 and other cost-effective engineered monoclonal antibodies for malaria prevention

Long-lasting and effective vaccines or monoclonal antibodies (mAbs) for malaria prevention are highly beneficial for people of all ages living in malaria-endemic regions. Recently, two highly protective human mAbs AB000224 (IGHV3-49/IGLV1-40) and AB007088 (IGHV3-33/IGKV1-5), which are encoded by different germline genes, were re-engineered and renamed as MAM01 and MS-1805, respectively, to improve their half-life, developability (including manufacturing), and cost-effectiveness according to WHO guidelines. MAM01 has completed phase 1 and 1b clinical trials (safety / PK / challenge) in US healthy naive adults and is in phase 1 trials (age-de-escalation studies) in Uganda. Here, we determined crystal structures of the antigen-binding fragments (Fabs) of engineered MAM01, MS-1805, and 7088 in complex with different regions of the Plasmodium falciparum (Pf) circumsporozoite protein (CSP), including junctional, minor, and major repeat regions. Notably, Fab 7088 features an extended CDRL3 comprising 10 amino acids (CDRL3:10) instead of the typical 8 amino acid CDRL3 (CDRL3:8) for V _H 3-33/V _K 1-5-encoded mAbs, revealing unique folding within its germline context. Structural comparisons showed that engineered antibodies retain the key molecular and hydrogen bond interactions with no significant conformational changes or loss in binding affinity. These findings demonstrate that the efficacy and affordability of human mAbs can be enhanced by selectively mutating residues in antibody framework regions without compromising binding affinity or epitope interaction.